Stay updated with breaking news from Regarding Use. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
All-Stock Transaction Combines Highly Complementary Businesses Unlocking Significant Benefits for Patients, Providers, Payers, and Care Teams
First Quarter 2023 Results Revenue totaled $445.4 million, an increase of 9.8% as compared to the same period in the prior year Net income was $24.8 million, an increase of 446.2% as compared... | May 4, 2023
First r/r ALL patient dosed in Europe with Cellectis’ UCART22 product candidate manufactured in-houseCellectis implements CLLS52 for the first time in the clinic with Sanofi’s... | May 4, 2023
/PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain...
First-Quarter 2023 Results: -- Net Sales of $832.1 Million -- -- GAAP Net Income of $54.7 Million; Adjusted EBITDA of $232.9 Million -- -- TEPEZZA® Net Sales of $405.3 Million -- --... | May 3, 2023